Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

Nicholas C. Turner(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Hugo M. Horlings, Rachael Natrajan(Institute of Cancer Research), Marc J. van de Vijver(The Netherlands Cancer Institute), Alan Mackay(Institute of Cancer Research), Rachel Sharpe(Guy's Hospital), Marieke van Kouwenhove(Amsterdam UMC Location University of Amsterdam), Felipe C. Geyer(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Bas Kreike(The Netherlands Cancer Institute), Maryou B. Lambros(Institute of Cancer Research), Alex Pearson(Breast Cancer Now)
Oncogene
January 18, 2010
10.1038/onc.2009.489
Cited by 416

Related Papers

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
The landscape of cancer genes and mutational processes in breast cancer
|Nature|2012|1.7k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k